@article{47ada6e422fd4fd9881dd59c6957a0d1,
title = "Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide",
abstract = "Regulatory T cells (TReg), CD4+CD25+FOXP3+, are implicated in suppressing tumor immune responses. We analyzed peripheral blood lymphocytes (PBL) from breast cancer patients receiving a modified HLA class II HER2/neu peptide (AE37) vaccine for TReg cells and correlated their levels with vaccine-specific immune responses. The mean CD4+CD25+FOXP3+ TReg cells decreased in patients with vaccination with no significant difference in serum TGF-β levels. IFN-γ ELISPOT and DTH increased after vaccination with a good correlation between TReg cell reduction and size of DTH to AE37. The TReg cell reduction and associated immune response suggest that AE37 may be clinically useful.",
keywords = "HER2/neu, Regulatory T cell, Vaccine",
author = "Gates, {Jeremy D.} and Clifton, {Guy T.} and Benavides, {Linda C.} and Sears, {Alan K.} and Carmichael, {Mark G.} and Hueman, {Matthew T.} and Holmes, {Jarrod P.} and Jama, {Yusuf H.} and Mohamed Mursal and Athina Zacharia and Kathy Ciano and Steven Khoo and Alexander Stojadinovic and Sathibalan Ponniah and Peoples, {George E.}",
note = "Funding Information: Supported by the United States Military Cancer Institute, Department of Surgery, Uniformed Services University of the Health Sciences, and the Department of Clinical Investigation at Walter Reed Army Medical Center. The clinical trial was funded by Antigen Express. ",
year = "2010",
month = nov,
day = "3",
doi = "10.1016/j.vaccine.2010.09.029",
language = "English",
volume = "28",
pages = "7476--7482",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "47",
}